Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
February 11, 2025 05:46 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
February 06, 2025 06:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
December 03, 2024 08:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
November 21, 2024 05:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
November 12, 2024 05:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
November 01, 2024 16:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
October 29, 2024 08:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
October 15, 2024 05:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
October 09, 2024 10:47 ET
|
Lipella Pharmaceuticals Inc.
PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases...
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
September 24, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus